Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT04372251
Active, not recruiting Not applicable

Osteosynthesis of Intraarticular Calcaneal Fractures: Arthroscopically Assisted Percutaneous Technique Versus Sinus Tarsi Approach

NCT04372251 · tracked via the Priya Life Science Norway tracker
Sponsor
Ostfold Hospital Trust
Phase
Not applicable
Started
2020-05-05
Last updated
2024-12-09

Condition(s) studied

Calcaneus Fracture

Investigational drug(s) / intervention(s)

Sinus tarsi approach (STA)Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)

Sinus tarsi approach (STA): Osteosynthesis

Percutaneous Arthroscopically Assisted Osteosynthesis (PACO): Osteosynthesis

Study summary

In this randomized controlled trial, the outcomes of two surgical techniques for intraarticular calcaneal fractures will be evaluated and compared.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Dislocated intraarticular calcaneal fracture, type Sanders II or Sanders III with an intraarticular step \> 2mm * Patients between 18 and 70 years of age * Acute presentation at one of our departments, enabling surgery within 10 days after injury Exclusion Criteria: * Intraarticular step of \< 2mm * Sanders IV fractures * Open fractures * Bilateral injuries * Concomitant major injuries of the foot, ankle or leg that affect the rehabilitation process * Multitraumized patients * Previous injury or surgery of the hindfoot * Charcot foot * Serious medical condition that contradicts surgery * Noncompliant patients * Insufficient Norwegian or English language skills * Patients not available for follow-up * Inability to conduct the rehabilitation protocol

Primary outcome measure(s)

  • Manchester-Oxford Foot Questionnaire (MOxFQ) — 5 years
    Foot-Ankle specific PROM (0-100 with 0 representing the best possible outcome)

Trial sites (5)

FacilityCityRegionStatus
Haukeland University Hospital Bergen Norway
Vestre Viken Hospital Trust - Drammen hospital Drammen Norway
Oslo university hospial Oslo Norway
Vestre Viken Hospital Trust - Bærum hospital Sandvika Norway
Østfold Hospital Trust Sarpsborg Østfold fylke

More Ostfold Hospital Trust trials in Norway

Use of Weightbearing Radiographs to Determine Treatment of bi- and Trimalleolar Ankle Fractures Active, not recruiting
The Benefit of Repairing the Deltoid Ligament in Unstable Ankle Fractures Recruiting
Stability and Outcomes of Non-displaced Lisfranc Injuries Active, not recruiting
Systematic Machine Learning Algorithm for Rapid Thrombosis Detection Recruiting
Weight-bearing Radiographs to Evaluate Stability in Ankles With Isolated Weber Type B Fractures. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04372251 on ClinicalTrials.gov ↗ ← All trials in Norway